Pharmaceuticals by P/E ratio
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Edgewise Therapeutics has the lowest figure of the 33 pharmaceuticals ranked by P/E ratio, at 4.9, followed by Alnylam Pharmaceuticals (7.7) and Novo Nordisk (10.0). Figures as of 18 Nov 2026, 15:42 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 33
- Lowest
- Edgewise Therapeutics4.9
- Median
- 40.2
- Combined market value
- SAR 19.06T
- Countries
- 10
- Not ranked
- 28no P/E ratio on file
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | P/E ↑ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Edgewise TherapeuticsEWTX · Health Care | 4.9 | SAR 16.7B | SAR 152.76 | 3.13% down | 88% up | ||
| 2 | Alnylam PharmaceuticalsALNY · Health Care | 7.7 | SAR 76.9B | SAR 574.03 | 2.21% down | 66% down | ||
| 3 | Novo NordiskNVO · Health Care | 10.0 | SAR 652.9B | SAR 148.15 | 2.96% down | 17% down | ||
| 4 | GrifolsGRFS · Health Care | 10.3 | SAR 21.7B | SAR 31.92 | 1.39% down | 1% up | ||
| 5 | Bristol-Myers SquibbBMY · Health Care | 13.3 | SAR 458.7B | SAR 224.42 | 2.48% down | 34% up | ||
| 6 | ZoetisZTS · Health Care | 14.2 | SAR 127.5B | SAR 313.85 | 0.23% up | 29% down | ||
| 7 | GSKGSK · Health Care | 17.0 | SAR 367.2B | SAR 183.20 | 0.81% down | 6% up | ||
| 8 | Ascendis PharmaASND · Health Care | 17.8 | SAR 66.4B | SAR 1,012.88 | 0.43% down | 28% up | ||
| 9 | Regeneron PharmaceuticalsREGN · Health Care | 21.1 | SAR 370.5B | SAR 3,581.94 | 0.30% down | 36% up | ||
| 10 | United TherapeuticsUTHR · Health Care | 21.5 | SAR 91.1B | SAR 2,138.16 | 2.41% down | 23% up | ||
| 11 | SanofiSNY · Health Care | 23.5 | SAR 425.9B | SAR 177.38 | 0.50% down | 4% down | ||
| 12 | AstraZenecaAZN · Health Care | 25.3 | SAR 1.04T | SAR 670.83 | 1.88% down | 2% up | ||
| 13 | Protagonist TherapeuticsPTGX · Health Care | 26.3 | SAR 30.5B | SAR 466.96 | 0.14% down | 46% up | ||
| 14 | NovartisNVS · Health Care | 29.8 | SAR 1.11T | SAR 586.58 | 1.73% down | 25% up | ||
| 15 | Vertex PharmaceuticalsVRTX · Health Care | 34.3 | SAR 507B | SAR 1,999.66 | 0.21% down | 27% up | ||
| 16 | Abbott LaboratoriesABT · Health Care | 38.9 | SAR 676.8B | SAR 390.78 | 0.51% down | 17% down | ||
| 17 | PfizerPFE · Health Care | 40.2 | SAR 601.7B | SAR 105.57 | 1.14% down | 14% up | ||
| 18 | Dr. Reddy's LaboratoriesRDY · Health Care | 41.5 | SAR 46.7B | SAR 56.06 | 1.05% up | 5% up | ||
| 19 | Johnson & JohnsonJNJ · Health Care | 41.7 | SAR 2.48T | SAR 1,031.56 | 1.32% down | 38% up | ||
| 20 | GenmabGMAB · Health Care | 43.8 | SAR 118.6B | SAR 192.28 | 1.35% down | 70% up | ||
| 21 | Royalty PharmaRPRX · Health Care | 44.7 | SAR 147.4B | SAR 256.34 | 0.50% down | 78% up | ||
| 22 | Eli LillyLLY · Health Care | 45.2 | SAR 4.65T | SAR 5,224.58 | 1.60% down | 35% up | ||
| 23 | AbbVieABBV · Health Care | 49.4 | SAR 1.91T | SAR 1,078.07 | 1.85% down | 26% up | ||
| 24 | Corcept TherapeuticsCORT · Health Care | 50.7 | SAR 27.7B | SAR 252.83 | 3.81% down | 8% down | ||
| 25 | BeOne MedicinesONC · Health Care | 51.7 | SAR 172.9B | SAR 1,513.55 | 2.36% down | 17% up | ||
| 26 | Amneal PharmaceuticalsAMRX · Health Care | 53.6 | SAR 28B | SAR 80.46 | 1.56% up | 83% up | ||
| 27 | Jazz PharmaceuticalsJAZZ · Health Care | 71.8 | SAR 58.4B | SAR 910.22 | 0.81% up | 37% up | ||
| 28 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | 72.3 | SAR 28.1B | SAR 358.22 | 0.41% up | 126% up | ||
| 29 | TG TherapeuticsTGTX · Health Care | 94.4 | SAR 35.9B | SAR 237.33 | 0.89% up | 107% up | ||
| 30 | Teva Pharmaceutical IndustriesTEVA · Health Care | 98.3 | SAR 185B | SAR 158.52 | 0.84% down | 74% up | ||
| 31 | Ligand PharmaceuticalsLGND · Health Care | 118 | SAR 22.1B | SAR 1,105.49 | 0.31% up | 43% up | ||
| 32 | Merck & CoMRK · Health Care | 141 | SAR 1.29T | SAR 524.05 | 2.55% down | 51% up | ||
| 33 | Takeda PharmaceuticalTAK · Health Care | 305 | SAR 256.2B | SAR 80.18 | 1.22% down | 54% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 3.7510 SAR). 28 companies have no P/E ratio on file and are not ranked here.
Questions and answers
Which pharmaceuticals have the lowest P/E ratio?
Edgewise Therapeutics (4.9), Alnylam Pharmaceuticals (7.7) and Novo Nordisk (10.0) have the lowest P/E ratio of the 33 pharmaceuticals ranked here as of 18 Nov 2026, 15:42 UTC.
How many pharmaceuticals are in this ranking?
33 are ranked by P/E ratio. 28 more have no P/E ratio on file and are left out rather than ranked at zero.
What are these pharmaceuticals worth together?
The 33 pharmaceuticals ranked by P/E ratio have a combined market value of SAR 19.06T as of 18 Nov 2026, 15:42 UTC.
What does ranking by P/E ratio measure?
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- PEG ratio: P/E adjusted for growth, and its limits
The PEG ratio is a stock's P/E divided by its expected yearly earnings growth in percent. A P/E of 20 with 10% expected growth gives a PEG of 2; with 20% growth, a PEG of 1. A PEG near 1 is the traditional rough mark of a fair price, but the growth figure is a forecast and often wrong.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Pharmaceuticals by P/E ratio”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=pe-ratio
Underlying data: Yahoo Finance; SEC EDGAR.